Double-blind randomized, crossover trial of calcium supplementation in essential hypertension. 1988

C Zoccali, and F Mallamaci, and D Delfino, and M Ciccarelli, and S Parlongo, and D Iellamo, and D Moscato, and Q Maggiore
Divisione di Nefrologia, Ospedali Riuniti, Reggio Cal, Italy.

In a double-blind, randomized, placebo-controlled, crossover trial, 23 middle-aged patients with mild to moderate essential hypertension were given an oral calcium supplement (1 g/day) for 8 weeks. At the end of this period, eight patients continued with this treatment for an additional 2 weeks but were also given 0.5 micrograms/day of 1,25-(OH)2 vitamin D3. In the 21 patients who completed the study, arterial pressure during the calcium-supplemented phase was almost identical to that of the placebo phase. In eight patients, mean arterial pressure (MAP) had changed by greater than 5 mmHg at the end of the calcium-supplemented period, compared with the end of the placebo phase (six patients showed an increase in MAP and two a decrease). Changes in arterial pressure were unrelated to age, plasma ionized calcium, parathyroid hormone (PTH), plasma renin activity (PRA), plasma aldosterone, 24-h urinary calcium, sodium and potassium and were only weakly related to body weight. In the eight patients who continued with the treatment of calcium plus 1,25-(OH)2 vitamin D3 after the 8-week study period, arterial pressure changed very little and not significantly. These results do not support the suggestion that calcium supplements lower arterial pressure in middle-aged subjects with mild to moderate essential hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002117 Calcitriol The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. 1 alpha,25-Dihydroxycholecalciferol,1 alpha,25-Dihydroxyvitamin D3,1, 25-(OH)2D3,1,25(OH)2D3,1,25-Dihydroxycholecalciferol,1,25-Dihydroxyvitamin D3,1 alpha, 25-dihydroxy-20-epi-Vitamin D3,1,25(OH)2-20epi-D3,1,25-dihydroxy-20-epi-Vitamin D3,20-epi-1alpha,25-dihydroxycholecaliferol,Bocatriol,Calcijex,Calcitriol KyraMed,Calcitriol-Nefro,Decostriol,MC-1288,MC1288,Osteotriol,Renatriol,Rocaltrol,Silkis,Sitriol,Soltriol,Tirocal,1 alpha,25 Dihydroxyvitamin D3,1,25 Dihydroxycholecalciferol,1,25 Dihydroxyvitamin D3,1,25 dihydroxy 20 epi Vitamin D3,Calcitriol Nefro,D3, 1 alpha,25-Dihydroxyvitamin,D3, 1,25-Dihydroxyvitamin,D3, 1,25-dihydroxy-20-epi-Vitamin,KyraMed, Calcitriol,MC 1288
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked

Related Publications

C Zoccali, and F Mallamaci, and D Delfino, and M Ciccarelli, and S Parlongo, and D Iellamo, and D Moscato, and Q Maggiore
February 1982, Lancet (London, England),
C Zoccali, and F Mallamaci, and D Delfino, and M Ciccarelli, and S Parlongo, and D Iellamo, and D Moscato, and Q Maggiore
July 2001, Circulation,
C Zoccali, and F Mallamaci, and D Delfino, and M Ciccarelli, and S Parlongo, and D Iellamo, and D Moscato, and Q Maggiore
May 2008, European journal of clinical nutrition,
C Zoccali, and F Mallamaci, and D Delfino, and M Ciccarelli, and S Parlongo, and D Iellamo, and D Moscato, and Q Maggiore
January 2015, Nitric oxide : biology and chemistry,
C Zoccali, and F Mallamaci, and D Delfino, and M Ciccarelli, and S Parlongo, and D Iellamo, and D Moscato, and Q Maggiore
January 1990, Psychopharmacology,
C Zoccali, and F Mallamaci, and D Delfino, and M Ciccarelli, and S Parlongo, and D Iellamo, and D Moscato, and Q Maggiore
February 1985, International journal of clinical pharmacology, therapy, and toxicology,
C Zoccali, and F Mallamaci, and D Delfino, and M Ciccarelli, and S Parlongo, and D Iellamo, and D Moscato, and Q Maggiore
January 1989, Journal of general internal medicine,
C Zoccali, and F Mallamaci, and D Delfino, and M Ciccarelli, and S Parlongo, and D Iellamo, and D Moscato, and Q Maggiore
October 1984, International journal of clinical pharmacology, therapy, and toxicology,
C Zoccali, and F Mallamaci, and D Delfino, and M Ciccarelli, and S Parlongo, and D Iellamo, and D Moscato, and Q Maggiore
June 2008, The American journal of clinical nutrition,
C Zoccali, and F Mallamaci, and D Delfino, and M Ciccarelli, and S Parlongo, and D Iellamo, and D Moscato, and Q Maggiore
December 2017, Scientific reports,
Copied contents to your clipboard!